Variant Perception

Where We Disagree With the Market

The sharpest disagreement is on FY2027, not FY2026. Sell-side consensus has anchored FY2027 EPS at $17.76 against an FY2026 number of $17.72 — a flat-line that simultaneously requires hospital EBITDA to take a $300–500M OBBBA Medicaid hit, the buyback flywheel to stall, and USPI same-facility growth to decelerate to the lower band, all in the same year. Each piece is plausible in isolation; the joint probability is not. The buyback math alone — at the FY2025 cadence of ~$1.39B annual repurchase against a ~$17B market cap — mechanically retires roughly 7–8% of the float and should lift per-share earnings even in a flat consolidated EBITDA scenario. Where we disagree is not direction (sell-side already sits at $240 vs. a $187 tape) but what the FY2027 anchor is implicitly worth — and the resolving signal is observable inside the next two earnings cycles.

A secondary disagreement runs in the opposite direction: the headline 10% FCF yield is real on paper but ~30% smaller after physician-JV distributions and the non-recurring Conifer contract buyout. Passive screens treat a $2.5–2.8B FCF guide as durable; the underlying owner-level cash flow is closer to $1.6–1.83B and the FY2026–2028 prints are inflated by ~$600M annually of one-time CommonSpirit cash. That gap is what makes the bull SOTP narrative deserve a haircut even if the FY2027 anchor is too low.

Variant Perception Scorecard

The 62 variant strength reflects three things at once: a clearly observable consensus signal (the FY2027 EPS line frozen one cent above FY2026 by 17–18 analysts), a quantifiable mechanical disagreement (buyback math + USPI mix), and a binary resolution path (OBBBA implementation rules in H2 2026 + management 2027 commentary at the Q3 call). It is not 80+ because the lead disagreement is bracketed by a real bear-side disagreement on FCF quality, and because USPI same-facility growth has to print at or above 5% for two consecutive quarters to validate the bullish leg.

Consensus Map

The cleanest consensus signal is the FY2027 EPS line — 18 sell-side analysts have collectively held it within one cent of FY2026, despite raising the FY2026 guide and acknowledging that EPTC ($250M, 2026) and OBBBA ($300–500M, 2027) are stacked headwinds on the same hospital book. The consensus map shows where that uncertainty lives: not in any single model assumption, but in an unwillingness to adjudicate the joint probability.

The Disagreement Ledger

Disagreement 1 — FY2027 EPS is anchored too low

The consensus view is that FY2027 EPS should print roughly flat to FY2026 because OBBBA Medicaid implementation and a stabilized hospital book together cancel out USPI growth and buybacks. Our evidence disagrees: the buyback math alone — $1.4B annually at the FY25 cadence against a $17B market cap — mechanically retires roughly 7–8% of the float per year, lifting per-share earnings even in a flat consolidated EBITDA case. Layer on top USPI's 76% commercial/Medicare mix (structurally insulated from Medicaid policy) and management's 2025 cost-discipline trajectory (SWB at 40.2% in Q4, best-in-class versus HCA ~41–42% and UHS ~46%), and a $300–400M hospital EBITDA hit from OBBBA still leaves per-share earnings growing 8–12% from FY2026. If we are right, consensus would have to concede a $1.50–$2.00 FY2027 EPS reset and roughly half the $187-vs-$240 PT gap closes on the numerator alone. The cleanest disconfirming signal is management refusing to provide directional 2027 commentary at the Q3 2026 call — that would tell us OBBBA exposure is bigger than we model.

Disagreement 2 — Hospital margin floor is ~16%, not the ~14% bear case embeds

The consensus view treats Q1 2026's same-hospital RPAA of -1.5% as evidence that the post-divestiture margin reset is fragile and that hospital EBITDA margin compresses 200 bps as exchange and Medicaid mix erode commercial. Our evidence disagrees: the 16.7% Q1 hospital margin already absorbs the EPTC step-down, commercial rates have been publicly described as "secured through 2027 above prior years," and the kept hospital portfolio is concentrated in TX/FL non-expansion-state markets where commercial payer mix is structurally stickier than the consolidated peer set. The bear is right that exchange admissions remain a 2026 headwind; we disagree on how much of that flows to margin, because (a) the kept facilities have higher commercial-share floors and (b) state-directed payment caps in OBBBA hit expansion-state programs harder than the non-expansion programs Tenet relies on. If we are right, ~200 bps of defended hospital margin is worth ~$300M of segment EBITDA — roughly $2–3B of equity value at 6–7x. The cleanest disconfirming signal is two consecutive quarters of hospital RPAA below -2%, or SWB ratio re-expanding above 41%.

Disagreement 3 — The "10% FCF yield" overstates owner-level economics by ~30%

This one runs against the bull. Independent valuation screens (AlphaSpread base case $312, ~40% undervalued) anchor on the FY2026 FCF guide of $2.5–2.8B and back out an attractive headline yield. Our evidence disagrees: ~$700M of segment cash leaks to noncontrolling-interest distributions before equity holders see a dollar (FY26 guide post-NCI: $1.6–1.83B), the $1.9B CommonSpirit-Conifer payment is a one-time contract buyout that inflates 2026–2028 CFO by ~$600M annually then disappears, and FY25 cash-taxes ran $821M below FY24 because the divestiture-gain tax bill was paid in the prior year. Strip those three out and durable owner-level FCF is closer to $1.7B — a ~9% equity yield rather than ~13%. Consensus would have to concede that the right multiple frame is closer to fair value than deep value, which doesn't break the bull case but caps the rerate beyond ~$220. The cleanest disconfirming signal is FY2026 reported FCF after NCI printing toward the high end of the $1.6–1.83B band with Conifer cash explicitly carved out — a sign the run-rate is genuinely $2.0B+.

Evidence That Changes the Odds

The evidence that does most of the work is items 1, 4, and 6. The flat FY2027 line is the consensus signal we are calling out; the geographic mix is the under-appreciated structural cushion against OBBBA; and the Conifer cash is the one-time contamination of headline FCF that limits how far the bull case can run. Items 3 (buyback) and 8 (Q1 conservatism) provide the mechanical bridge to the higher FY27 number.

How This Gets Resolved

The decision is resolved inside two quarters. Q2 2026 earnings (late July) update the FY26 guide and the hospital-margin trajectory; Q3 2026 earnings (late October) deliver the first directional FY2027 commentary; and CMS/Treasury OBBBA rules in H2 2026 bound the worst-case hospital scenario. None of this requires waiting five years for the moat to be tested — every leg of the variant view has a dated, observable signal.

What Would Make Us Wrong

The lead disagreement breaks if any one of three things happens. First, OBBBA implementation rules issued in H2 2026 bind state-directed payments more aggressively than we model — specifically, if Texas and Florida provider-tax programs are re-classified as state-directed payments under the new framework, the hospital EBITDA hit can reach $500M annually rather than the $300M we treat as the realistic case. This would push FY2027 EBITDA below FY2026 and the consensus flat-line stops looking too low. Second, the buyback cadence stalls. If management redirects $500M+ of FY26 capital to a meaningful USPI M&A deal (e.g., to backfill the 533 vs. 600 unit miss) or to balance-sheet preservation ahead of an SEC enforcement resolution, the mechanical EPS lift we lean on disappears and the FY27 anchor becomes harder to dispute. Third, USPI same-facility growth prints below 5% for two quarters running. Q1 was 5.3% — close to the bear edge. If Optum/SCA Health begins systematically excluding USPI ASCs from UnitedHealth narrow networks, same-facility growth could compress to 3% and the segment EBITDA growth that funds the variant FY27 bridge collapses.

The hospital margin floor disagreement breaks if commercial rates start to crack — specifically if any of the active payer disputes (Cigna/Abrazo, Humana renegotiations) extends into a network exclusion or rate-cut settlement, or if the "secured through 2027" language proves to be top-line guidance that comes with give-backs on volume share. The same-hospital RPAA at -1.5% in Q1 needs to stabilize at flat by Q3 for our hospital floor case to hold.

The FCF-quality bear-side disagreement breaks if Conifer wins a major 2027 client backfill — a large health-system RCM contract announced before year-end 2026 would partially offset the CommonSpirit cliff and lift durable post-2028 FCF, narrowing the gap between headline and owner-level cash flow. It also breaks if management buys out a meaningful slice of the USPI physician-JV minority stake at a reasonable multiple, which would reduce NCI leakage.

We are most likely to be wrong on the lead disagreement if the SEC FOIA 7(A) enforcement matter becomes public — that is a re-rate event independent of operating fundamentals, and it would dominate any FY2027 EPS reset for at least two quarters of headline risk.

The first thing to watch is the Q3 2026 earnings call commentary on FY2027 — specifically whether management offers a quantified or directional 2027 EBITDA bridge that incorporates a non-zero OBBBA assumption. That single disclosure resolves whether consensus holding the FY2027 EPS line one cent above FY2026 is the analytically correct answer or the lazy one.